3rd generation drug for acquired resistance in egfr lung cancer
Published 10 years ago • 482 plays • Length 4:10Download video MP4
Download video MP3
Similar videos
-
11:36
azd9291 for acquired resistance in egfr positive lung cancer
-
3:07
third generation egfr tkis for acquired resistance
-
3:22
acquired resistance in lung cancer treatment - lcvl 2024
-
3:02
resistance mechanisms in egfr nsclc treatment - targeted therapies in lung cancer 2023
-
10:16
overcoming resistance in egfr nsclc - lung cancer onctalk 2022
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
4:10
egfr mutations in advanced nsclc - targeted therapies in lung cancer 2023
-
6:26
metastatic egfr nsclc: recent developments - targeted therapies in lung cancer 2023
-
4:26
combinations and other options for acquired resistance in egfr mutation-positive nsclc
-
3:28
should third generation egfr inhibitors be used before or after progression?
-
4:22
what is egfr in lung cancer? - 2022 program: targeted therapies forum
-
4:02
egfr resisters: an advocacy group - targeted therapies in lung cancer 2023
-
28:22
gracecast-088_lung-cancer_challenging cases in lung cancer: acquired resistance to egfr tki therapy
-
2:26
patterns of acquired resistance to egfr tkis in egfr mutation-positive nsclc
-
4:40
ntrk nsclc: treatment options and side effects - targeted therapies in lung cancer 2023
-
5:09
should a third generation egfr inhibitor be first line therapy for egfr mutation-positive nsclc?
-
3:24
options for egfr mutation-positive patients with t790m mutation-negative acquired resistance
-
3:25
are there significant differences among the 1st and 2nd generation egfr tkis?
-
1:17
co-1686: third generation drug for egfr positive lung cancer patients